Telix Pharmaceuticals Ltd
corporate_fare Company Profile
Telix Pharmaceuticals Ltd (NASDAQ:TLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for TLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-02, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for TLX spans 6-K, 4.
Recent high-impact activity:
- Telix Completes Enrollment in Pivotal BiPASS Trial, FDA Aligns on NDA Path
- Telix Completes Phase 3 BiPASS Enrollment, Aligns with FDA on NDA Pathway
- Telix H1 Revenue Jumps 22% to $477M, EBITDA Up 146%, Regeneron Deal Adds $40M
- Telix Q2 Revenue Reaches $247M, FY2026 Guidance Lifted Above $1B
- Telix Q2 Revenue Hits $247M, Raises FY Outlook to Over $1B
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for TLX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-20.
ATM Facility Established · Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
TLX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.